Evidence map›Paper›PMID 30653090›Full record

SynthesisMedicine2019

Systemic immune-inflammation index is a promising noninvasive marker to predict survival of lung cancer: A meta-analysis.

Yi Zhang, Bo Chen, Lijuan Wang, Rong Wang, Xianjin Yang

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 12 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 12 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yi ZhangDepartment of General Surgery.
Bo ChenDepartment of Cardiology, the First People's Hospital of Neijiang, Neijiang, Sichuan Province.
Lijuan WangDepartment of Nephrology, Shangrao People's Hospital, Shangrao, Jiangxi Province, P. R. China.
Rong WangDepartment of General Surgery.
Xianjin YangDepartment of General Surgery.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prognostic value of pretreatment systemic immune-inflammation index (SII) in lung cancer has yet to be fully established.

methodsRelevant articles were obtained by performing a systematic search. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were used to assess the relationship between SII index and overall survival (OS) in lung cancer; the OS was calculated from the time of cancer diagnosis to the date of death due to any cause or to the last date of follow-up.

resultsIn total, 2786 patients with lung cancer from 7 studies were included in this meta-analysis. The median thresholds to define high SII was 640 (range 395.4-1600) in the analyzed studies. The pooled HR for OS was 1.77 (95% CI: 1.54-2.00, P < .001), suggesting that the patients with a high SII score had a worse OS. In addition, results from subgroup meta-analysis showed the significant prognostic significance of SII in lung cancer. Especially, the predictive value of SII was significant in the multivariable model for NSCLC (HR: 1.97, 95% CI: 1.69-2.25, P < .001; 5 studies, 1746 patients), and SCLC (HR: 1.38, 95% CI: 1.02-1.85, P < .001; 1 study, 919 patients).

conclusionOur data suggest that high SII index indicates poor survival rate in lung cancer. Further researches are warranted to verify the significance of SII index in clinical practice.

Indexed as

AdultAgedBiomarkersCarcinoma, Non-Small-Cell LungFemaleHumansInflammationLung NeoplasmsMaleMiddle AgedPredictive Value of TestsPrognosisRetrospective StudiesBiomarkers

Identifiers

PMID30653090
PMCPMC6370019

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.